Subject:
- Active Sustance: Trastuzumab Deruxtecan
- Name: Enhertu®
- Therapeutic area: Breast cancer
- Pharmaceutical company: Daiichi Sankyo Deutschland GmbH
Time table:
- Start: 01.08.2022
- Final decision by G-BA: 02.02.2023
Final decision:
- Indication for a non-quantifiable additional benefit